The 3 analysts offering 12-month price forecasts for Adagio Therapeutics Inc have a median target of 3.50, with a high estimate of 5.00 and a low estimate of 3.00. The median estimate represents a +18.24% increase from the last price of 2.96.
The current consensus among 4 polled investment analysts is to Hold stock in Adagio Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.53
Reporting Date Sep 19
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.